{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000016","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.031299+00:00","generated_at":"2026-06-05T08:59:52.705954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Keros Therapeutics reports Q4 2023 net loss of $40.2M, cash $331.1M; extends runway into 2027","bullets":["Net loss of $40.2M in Q4 2023 ($153.0M for FY) vs $29.7M and $104.7M in prior year periods.","Revenue of $0.2M in 2023 from license agreement with Hansoh; no revenue in 2022.","R&D expenses rose to $37.5M in Q4 (FY $135.3M) driven by Phase 2 trials of KER-050 and KER-012.","Cash and equivalents $331.1M at Dec 31, 2023; January 2024 public offering of 4.025M shares at $40/sh adds net proceeds, funding into 2027.","Anticipated milestones: Phase 3 trial design for KER-050 in MDS in H1 2024; data readouts throughout 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000016","json":"https://secwatch.observer/filing/0001664710-24-000016.json","markdown":"https://secwatch.observer/filing/0001664710-24-000016.md","text":"https://secwatch.observer/filing/0001664710-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/0001664710-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/kros-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:59:52.705954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"346f8654c63213322a629ece76ca7bf01df88f20","claim":"Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.2 million for the year ended December 31, 2023, net income a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023.","evidence_excerpt":"Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/0001664710-24-000016-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$0.2 million for the year ended December 31, 2023"},{"label":"Net income","value":"a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}